Daily Newsletter

05 September 2023

Daily Newsletter

05 September 2023

Chinese NMPA approves AstraZeneca’s Calquence for leukaemia

ASCEND findings showed that 88% of subjects were alive and free from disease progression following treatment with Calquence.

Vishnu Priyan September 05 2023

The Chinese National Medical Products Administration (NMPA) has granted approval for AstraZeneca’s Calquence (acalabrutinib) to treat chronic lymphocytic leukaemia (CLL) or small lymphocytic lymphoma (SLL) in adults.

A selective inhibitor of Bruton’s tyrosine kinase (BTK), Calquence is indicated for use in CLL or SLL patients who have received a minimum of one treatment previously.

The approval was based on positive data from two clinical trials; namely, the Phase III ASCEND trial of Calquence in relapsed or refractory (R/R) CLL patients and a Phase I/II trial in R/R CLL patients in China.

According to the data from the Phase I/II trial, treatment with Calquence offered an overall response rate of 83.3% in study subjects.

ASCEND findings showed that 88% of trial subjects were alive and free from disease progression after 12 months following treatment with Calquence.

AstraZeneca oncology business unit executive vice-president Dave Fredrickson said: “The approval is another step towards our goal of making Calquence available to as many patients as possible and offering physicians a treatment option with a well-established efficacy and tolerability profile. 

“Patients with chronic lymphocytic leukaemia are often older and dealing with significant comorbidities, and tolerability is a critical factor in their treatment.”

Calquence is currently available for treating CLL and SLL in the US and Japan while it is indicated for CLL in the R/R and treatment-naïve patients in the EU and other countries globally. 

Apart from CLL, the product is also being analysed by the company to treat multiple B-cell blood cancers; namely, mantle cell lymphoma (MCL), diffuse large B-cell lymphoma, Waldenström’s macroglobulinaemia and marginal zone lymphoma, among others.

In March 2023, the Chinese regulator granted conditional approval for Calquence for the treatment of MCL in adults who have received a minimum of one earlier therapy.

M&A in the Contract Manufacturing Industry

Despite challenging business conditions in 2021 and 2022, large CMOs were still involved in acquisitions to enhance their capabilities or scale of production. Catalent and Recipharm were particularly active in acquiring companies during this period, and these acquisitions had a focus on advanced biologic capabilities related to cell and gene therapies. CMOs are increasingly targeting companies with sophisticated (biologic and specialized) capabilities to manufacture modern drugs and seek high-value contracts.

Newsletters by sectors

close

Sign up to the newsletter: In Brief

Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Thank you for subscribing

View all newsletters from across the GlobalData Media network.

close